DETANONOate is a potent chemo\radio-sensitizing agent in colon and colorectal cancers as assessed in in vitro and in vivo established tumor xenografts

Forum on Immunopathological Diseases and Therapeutics

Volumn 1, Issue 4, 2010, Pages 281-295

  Huerta, Sergio ^a   Gao, Xiaohuan ^a   Bonavida, Benjamin ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

AIF; BAX; Ionizing radiation; Pathological complete response; Rectal cancer

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; APOPTOSIS INDUCING FACTOR; CISPLATIN; NITRIC OXIDE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27;

APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER RADIOTHERAPY; COLON CANCER; COLONY FORMATION; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; DOWN REGULATION; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECTUM CANCER; SW620 CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION;

EID: 84862951120     PISSN: 21518017     EISSN: 21518025     Source Type: Journal    
DOI: 10.1615/ForumImmunDisTher.v1.i4.30     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-49.
2. Huerta S. Recent advances in the molecular diagnosis and prognosis of colorectal cancer. Expert Rev Mol Diagn. 2008;8:277-88.
3. Wolpin BM, Meyerhardt JA, Mamon HJ, Mayer RJ. Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007;57:168-85.
4. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004;96:1420-5.
5. Huerta S, Li C. Small bowel obstruction due to metastatic colon cancer. Anti-Cancer Drugs. 2009;20:S15-8.
6. Huerta S, Li HC. Bowel perforation from bevacizumab for the management of colorectal cancer. Anti-Cancer Drugs. 2009;20:S19-21.
7. Huerta S, Li HC. Bevacizumab-associated hypertension: etiology, incidence, and management. Anti-Cancer Drugs. 2009;20;S22-4.
8. Ridnour LA, Thomas DD, Switzer C, Flores-Santana W, Isenberg JS, Ambs S, Roberts DD, Wink DA. Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide. 2008;19:73-6.
9. Wink DA, Ridnour LA, Hussain SP, Harris CC. The reemergence of nitric oxide and cancer. Nitric Oxide. 2008;19:65-7.
10. Huerta S, Chilka S, Bonavida B. Nitric oxide donors: novel cancer therapeutics (review). Int J Oncol. 2008;33:909-27.
11. Huerta S, Baay-Guzman G, Gonzalez-Bonilla CR, Livingston EH, Huerta-Yepez S, Bonavida B. In vitro and in vivo sensitization of SW620 metastatic colon cancer cells to CDDP-induced apoptosis by the nitric oxide donor DETANONOate: Involvement of AIF. Nitric Oxide. 2009;20:182-94.
12. Gao X, Saha D, Kapur P, Anthony T, Livingston EH, Huerta S. Radio-sensitization of HT-29 cells and xenografts by the nitric oxide donor DETANONOate. J Surg Oncol. 2009;100:149-58.
13. Vodovotz Y, Chesler L, Chong H, Kim SJ, Simpson JT, DeGraff W, Cox GW, Roberts AB, Wink DA, Barcellos-Hoff MH. Regulation of transforming growth factor betal by nitric oxide. Cancer Res. 1999;59: 2142-9.
14. Pervin S, Singh R, Chaudhuri G. Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin Dl. Proc Natl Acad Sci USA. 2001;98:3583-8.
15. Muir CP, Adams MA, Graham CH. Nitric oxide attenuates resistance to doxorubicin in three-dimensional aggregates of human breast carcinoma cells. Breast Cancer Res Treat. 2006;96:169-76.
16. Pervin S, Singh R, Gau CL, Edamatsu H, Tamanoi F, Chaudhuri G. Potentiation of nitric oxide-induced apoptosis of MDA-MB-468 cells by farnesyltransferase inhibitor: implications in breast cancer. Cancer Res. 2001;61:4701-6.
17. Matthews NE, Adams MA, Maxwell LR, Gofton TE, Graham CH. Nitric oxide-mediated regulation of chemosensitivity in cancer cells. J Natl Cancer Inst. 2001;93:1879-85.
18. Azizzadeh B, Yip HT, Blackwell KE, Horvath S, Calcaterra TC, Buga GM, Ignarro LJ, Wang MB. Nitric oxide improves cisplatin cytotoxicity in head and neck squamous cell carcinoma. Laryngoscope. 2001;111:1896-900.
19. Wink DA, Cook JA, Christodoulou D, Krishna MC, Pacelli R, Kim S, DeGraff W, Gamson J, Vodovotz Y, Russo A, Mitchell JB. Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide. 1997;1:88-94.
20. Perrotta C, Bizzozero L, Falcone S, Rovere-Querini P, Prinetti A, Schuchman EH, Sonnino S, Manfredi AA, Clementi E. Nitric oxide boosts chemoimmunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma. Cancer Res. 2007;67:7559-64.
21. Huerta S, Harris DM, Jazirehi A, Bonavida B, Elashoff D, Livingston EH, Heber D. Gene expression profile of metastatic colon cancer cells resistant to cisplatin-induced apoptosis. Int J Oncol. 2003;22:663-70.
22. Huerta S, Anguiano-Hernandez YM, Goulet EJ, Huerta-Yepez S, Livingston EH. Decreased levels of AIF renders resistance to oxaliplatin mediated apoptosis in the progression of colon cancer carcinogenesis beyond caspase-3 activity. Am J Gastroenterol. 2006;10:S196.
23. Huerta S, Heinzerling JH, nguiano-Hernandez YM, Huerta-Yepez S, Lin J, Chen D, Bonavida B, Livingston EH. Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J Surg Res. 2007;142:184-94.
24. Daugas E, Nochy D, Ravagnan L, Loeffler M, Susin SA, Zamzami N, Kroemer G. Apoptosis-inducing factor (AIF): a ubiquitous mitochondrial oxidoreductase involved in apoptosis. FEBS Lett. 2000;476:118-23.
25. Park YC, Jeong JH, Park KJ, Choi HJ, Park YM, Jeong BK, Higuchi Y, Yoo YH. Sulindac activates nuclear translocation of AIF, DFF40 and endonuclease G but not induces oligonucleosomal DNA fragmentation in HT-29 cells. Life Sci. 2005;77:2059-70.
26. Onoda T, Ono T, Dhar DK, Yamanoi A, Nagasue N. Tetracycline analogues (doxycycline and COL-3) induce caspase-dependent and -independent apoptosis in human colon cancer cells. Int J Cancer. 2006;118:1309-15.
27. Lin JC, Ho YS, Lee JJ, Liu CL, Yang TL, Wu CH. Induction of apoptosis and cell-cycle arrest in human colon cancer cells by meclizine. Food Chem Toxicol. 2007;45:935-44.
28. Erhart LM, Lankat-Buttgereit B, Schmidt H, Wenzel U, Daniel H, Goke R. Flavone initiates a hierarchical activation of the caspase-cas-cade in colon cancer cells. Apoptosis. 2005;10:611-7.
29. Rashmi R, Kumar S, Karunagaran D. Human colon cancer cells lacking Bax resist curcumin-induced apoptosis and Bax requirement is dispensable with ectopic expression of Smac or downregulation of Bcl-XL. Carcinogenesis. 2005;26:713-23.
30. Diaz GD, Li Q, Dashwood RH. Caspase-8 and apoptosis-inducing factor mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytochemical chlorophyllin. Cancer Res. 2003;63:1254-61.
31. Ho YS, Wu CH, Chou HM, Wang YJ, Tseng H, Chen CH, Chen LC, Lee CH, Lin SY. Molecular mechanisms of econazole-induced toxicity on human colon cancer cells: G0/G1 cell cycle arrest and caspase 8-independent apoptotic signaling pathways. Food Chem Toxicol. 2005;43:1483-95.
32. Millan A, Huerta S. Apoptosis-inducing factor and colon cancer. J Surg Res. 2009;151:163-70.
33. Schmitt E, Maingret L, Puig PE, Rerole AL, Ghiringhelli F, Hammann A, Solary E, Kroemer G, Garrido C. Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma. Cancer Res. 2006;66:4191-7.
34. Forrester K, Ambs S, Lupoid SE, Kapust RB, Spillare EA, Weinberg WC, Felley-Bosco E, Wang XW, Geller, DA, Tzeng E, Billiar TR, Harris CC. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA. 1996;93:2442-7.
35. Messmer UK, Brune B. Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways. Biochem J. 1996;319: 299-305.
36. Glockzin S, von KA, Scheffner M, Brune B. Activation of the cell death program by nitric oxide involves inhibition of the proteasome. J Biol Chem. 1999;274:19581-6.
37. Li CQ, Robles AI, Hanigan CL, Hofseth LJ, Trudel LJ, Harris CC, Wogan GN. Apoptotic signaling pathways induced by nitric oxide in human lymphoblastoid cells expressing wild-type or mutant p53. Cancer Res. 2004;64:3022-9.
38. Boyd CS, Cadenas E. Nitric oxide and cell signaling pathways in mito-chondrial-dependent apoptosis. Biol Chem. 2002;383:411-23.
39. Bonavida B, Khineche S, Huerta-Yepez S, Garban H. Therapeutic potential of nitric oxide in cancer. Drug Resist Updat. 2006;9:157-73.
40. Kroncke KD, Fehsel K, Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. Clin Exp Immunol. 1998;113:147-56.
41. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2001;2:149-56.
42. Shimaoka M, Iida T, Ohara A, Taenaka N, Mashimo T, Honda T, Yoshiya I. NOC, a nitric-oxide-releasing compound, induces dose dependent apoptosis in macrophages. Biochem Biophys Res Commun. 1995;209:519-26.
43. Heller R, Polack T, Grabner R, Till U. Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP. Atherosclerosis. 1999;144:49-57.
44. Voland C, Bord A, Peleraux A, Penarier G, Carriere D, Galiegue S, Cvitkovic E, Jbilo O, Casellas P. Repression of cell cycle-related proteins by oxaliplatin but not cisplatin in human colon cancer cells. Mol Cancer Ther. 2006;5:2149-57.
45. Liu Q, Chan ST, Mahendran R. Nitric oxide induces cyclooxygenase expression and inhibits cell growth in colon cancer cell lines. Carcinogenesis. 2003;24:637-42.
46. Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, Kalala S, Traganos F, Benardini F, del Soldato P, Kashfi K, Rigas, B. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol. 2004;67: 2197-205.
47. Dejardin E, Deregowski V, Chapelier M, Jacobs N, Gielen J, Merville MP, Bours V. Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene. 1999;18:2567-77.
48. Shibata D, Peinado MA, Ionov Y, Malkhosyan S, Perucho M. Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet. 1994;6:273-81.
49. Siegert A, Rosenberg C, Schmitt WD, Denkert C, Hauptmann S. Nitric oxide of human colorectal adenocarcinoma cell lines promotes tumour cell invasion. Br J Cancer. 2002;86:1310-5.
50. Huerta S, Gao X, Saha D. Mechanisms of resistance to ionizing radiation in rectal cancer. Expert Rev Mol Diagn. 2009;9:469-80.
51. Huerta S, Anguiano-Hernandez Y, Gonzalez-Bonilla CR, Huerta-Yepez S, Livingston EH. DETA/NONOate-mediated chemosensitization to cisplatin-induced apoptotis of colon cancer in vitro and in vivo. J Surg Res. 2007;137:271.
52. Yasuda H, Yamaya M, Nakayama K, Sasaki T, Ebihara S, Kanda A, Asada M, Inoue D, Suzuki T, Okazaki T, Takahashi H, Yoshida M, Kaneta T, Ishizawa K, Yamanda S, Tomita N, Yamasaki M, Kikuchi A, Kubo H, Sasaki H. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol. 2006;24:688-94.